🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesHas anyone dealt with prediabetes reversal on glp-1?

Has anyone dealt with prediabetes reversal on glp-1?

tony_orlando Sat, Feb 28, 2026 at 1:54 PM 9 replies 810 viewsPage 1 of 2
tony_orlando
Member
234
1,123
Nov 2024
Orlando, FL
Feb 28, 2026 at 1:54 PM#1

Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.

What I actually want to know is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.

Practical detail welcome, however dull — the duller the better.

6 1NauseaFreeNow, SteveThurs, B12Beth and 3 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Feb 28, 2026 at 2:11 PM#2
tony_orlando said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 11 months: periods became regular for the first time in a decade, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my fertility specialist is optimistic about future conception.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

5 0Admin, Dr.Martinez, mike_mod and 2 others
Reply Quote Save Share Report
SallyK_inj
Member
567
2,345
Jul 2024
Iowa
Feb 28, 2026 at 2:28 PM#3
FDA_TrackerJim said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 25 → 15 → 7 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

4 24oliver_london, tane_welly, Dr.PathRoch and 1 other
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
CryptoCarl
Member
789
3,456
May 2024
Arizona
Feb 28, 2026 at 2:45 PM#4
tony_orlando said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

This matches mine closely enough to be worth saying so out loud. The detail I would add is minor and it is already implied above.

3 23BethLabQueen, ChrisMacros, KetoKyle
Reply Quote Save Share Report
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Feb 28, 2026 at 4:18 PM#5

Adding the clinical framing, because it changes how the question reads.

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 21%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

2 22JessicaM_2024, TomFromTexas
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register